Brodalumab for the treatment of psoriasis

References

• Parisi R, Symmons D, Griffiths CE, et al. (On behalf of IMPACT team). Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8). pii: 13030/qt48r4w8h2.
   Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282–1290.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–872.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233–240.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Marinoni B, Ceribelli A, Massarotti MS, et al. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9–19.
   PubMedGoogle Scholar
• Speeckaert R, Lambert J, Grine L, et al. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. 2016 Apr 26. doi: 10.1111/bjd.14703. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150.
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol. 2007;8(9):950–957.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Figueiredo A, Santos-Silva A. Brodalumab: an evidence-based review of its potential in the treatment of moderate-nto-severe psoriasis. Core Evid. 2014;9:89–97.
   PubMedGoogle Scholar
• Iwakura Y, Nakae S, Saijo S, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57–79.
   PubMed Web of Science ®Google Scholar
• Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol. 2007;51(12):1139–1147.
   PubMed Web of Science ®Google Scholar
• Isailovic N, Daigo K, Mantovani A, et al. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–776.
   PubMed Web of Science ®Google Scholar
• Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457(7230):722–725.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Invest Drugs. 2013;22(8):993–1005.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52–72.
   Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–429.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–144.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti- IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo- controlled trial. Br J Dermatol. 2015;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–3836.
   PubMed Web of Science ®Google Scholar
• Martin DA, Churchill M, Flores-suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R164.
   PubMed Web of Science ®Google Scholar
• Osamu N, Hirotaka N, Koji S, et al. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo controlled study. J Dermatol Sci. 2014;75(3):201–204.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Salinger DH, Kӧck K, et al. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol. 2014;54(11):1230–1238.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase i, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469.
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183–1190.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niirob H, Ootaki K, et al. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nakagawa H, Niiro H, et al. Japanese Brodalumab Study Group. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016 Jun 29. doi: 10.1111/jdv.13785. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Strober B, et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to severe plaque psoriasis. J Am Acad Dermatol. 2015;72(3):436–439.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective Phase 3, randomized, double-blind, placebo controlled study of brodalumab in patients with moderate-to severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2016. published online 23 Apr 2016. doi:10.1111/bjd.14702 [Epub ahead of print]
   Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Greig SL. Brodalumab: first global approval. Drugs. 2016 Sep;76(14):1403–1412.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. AstraZeneca enters licensing agreements with LEO Pharma in skin diseases [media release]. [cited 2016 Jul 1]. Available from: http://www.astrazeneca.com
   Google Scholar
• Valeant Pharmaceuticals International. Valeant Pharmaceuticals announces new licensing arrangement for brodalumab in Europe [media release]. [cited 2016 Jul 1]. Available from: http://www.valeant.com
   Google Scholar
• Available from: https://www.drugs.com/nda/brodalumab_160719.html
   Google Scholar
• Available from: http://www.medscape.com/viewarticle/866406?nlid=108537_1585&src=WNL_mdplsfeat_160726_mscpedit_derm&uac=208695CJ&spon=33&impID=1166274&faf=1
   Google Scholar
• Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo controlled study through week 12. Presented at the 73rd annual meeting of the American academy of dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• AbuHilal M, Walsh S, Shear N. The role of IL-17 in the pathogenesis of Psoriasis and update on IL-17 inhibitors for the treatment of plaque Psoriasis. J Cutan Med Surg. 2016. pii: 1203475416651605. [Epub ahead of print]
   Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–68.
   PubMed Web of Science ®Google Scholar
• Boisson B, Wang C, Pedergnana V, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39(4):676–686.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3):311–316.
   PubMedGoogle Scholar
• Hueber W, Sands B, Lewitzky S, et al. Secukinumab, a human anti-IL17a monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Vermiere S, et al. A randomized, double blind, placebo controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology. 2012;143(3):E26.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–850.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190–192.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. Highlights of prescribing information. [cited 2015 Jul 5]. Available from: http://www.otezla.com/otezla-prescribinginformation.pdf
   Google Scholar
• Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–193.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–429.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon K-YT-Y, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250.
   PubMed Web of Science ®Google Scholar
• De Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses. 2004;63(4):696–698.
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–950.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatol Basel Switz. 2008;216:260–270.
   PubMed Web of Science ®Google Scholar